Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center
The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identif...
Gespeichert in:
| Veröffentlicht in: | Revista de investigacion clinica 2020-10, Vol.73 (5), p.94-99 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 99 |
|---|---|
| container_issue | 5 |
| container_start_page | 94 |
| container_title | Revista de investigacion clinica |
| container_volume | 73 |
| creator | Córdova-Ramírez, Alejandra C Sánchez-Valledor, Luisa F Colón-Otero, Gerardo Rivera-Alvarez, Montserrat Elías-de-la-Cruz, Gilberto D Murrieta-Alvarez, Iván Cantero-Fortiz, Yahveth León-Peña, Andrés Olivares-Gazca, Juan C Ruiz-Delgado, Guillermo J Ruiz-Argüelles, Guillermo J |
| description | The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México.
This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified.
There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006).
Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy. |
| doi_str_mv | 10.24875/RIC.20000381 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0034_83762021000200094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0034_83762021000200094</scielo_id><sourcerecordid>2452499252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c257t-5d4606a21855ddfce0618f2ce75ae5a5411edbf0174871cb93c69885fffd20573</originalsourceid><addsrcrecordid>eNo9UU1PAyEQ5aCxWj16NRy9bAV22Q9vpvErsTGpeiYUBsWwS4WtWn-9bGudy0smb97MvIfQKSUTVtQVv5jfTyeMpMpruocOExZZnVflCB3F-E4IY4xXB2iU56TipGCHKM5k1zvACpzDbt0u33wrcSvX-E1-ApZYW2MgQNdj5WxnlXRY-VWIgG2HZ_CdOgPG3v74eInnIF325YPTWMteYhN8m1Si7V43W7oewjHaN9JFOPnDMXq5uX6e3mUPj7f306uHTKUr-4zroiSlZLTmXGujgJS0NkxBxSVwyQtKQS8MoVX6napFk6uyqWtujNGM8Cofo8lWNyoLzov3dHeXFoqnwRgxGMMIo8muwbOmSAPn24Fl8B-r9JNobRyckR34VRSs4KxoGsZZomZbqgo-xgBGLINtZVgLSsQmDJHCELswEv_sT3q1aEH_s3dJ5L9llYQ5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452499252</pqid></control><display><type>article</type><title>Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Córdova-Ramírez, Alejandra C ; Sánchez-Valledor, Luisa F ; Colón-Otero, Gerardo ; Rivera-Alvarez, Montserrat ; Elías-de-la-Cruz, Gilberto D ; Murrieta-Alvarez, Iván ; Cantero-Fortiz, Yahveth ; León-Peña, Andrés ; Olivares-Gazca, Juan C ; Ruiz-Delgado, Guillermo J ; Ruiz-Argüelles, Guillermo J</creator><creatorcontrib>Córdova-Ramírez, Alejandra C ; Sánchez-Valledor, Luisa F ; Colón-Otero, Gerardo ; Rivera-Alvarez, Montserrat ; Elías-de-la-Cruz, Gilberto D ; Murrieta-Alvarez, Iván ; Cantero-Fortiz, Yahveth ; León-Peña, Andrés ; Olivares-Gazca, Juan C ; Ruiz-Delgado, Guillermo J ; Ruiz-Argüelles, Guillermo J</creatorcontrib><description>The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México.
This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified.
There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006).
Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.</description><identifier>ISSN: 0034-8376</identifier><identifier>ISSN: 2564-8896</identifier><identifier>DOI: 10.24875/RIC.20000381</identifier><identifier>PMID: 33075042</identifier><language>eng</language><publisher>Mexico: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</publisher><subject>Medicine, General & Internal</subject><ispartof>Revista de investigacion clinica, 2020-10, Vol.73 (5), p.94-99</ispartof><rights>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33075042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Córdova-Ramírez, Alejandra C</creatorcontrib><creatorcontrib>Sánchez-Valledor, Luisa F</creatorcontrib><creatorcontrib>Colón-Otero, Gerardo</creatorcontrib><creatorcontrib>Rivera-Alvarez, Montserrat</creatorcontrib><creatorcontrib>Elías-de-la-Cruz, Gilberto D</creatorcontrib><creatorcontrib>Murrieta-Alvarez, Iván</creatorcontrib><creatorcontrib>Cantero-Fortiz, Yahveth</creatorcontrib><creatorcontrib>León-Peña, Andrés</creatorcontrib><creatorcontrib>Olivares-Gazca, Juan C</creatorcontrib><creatorcontrib>Ruiz-Delgado, Guillermo J</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo J</creatorcontrib><title>Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center</title><title>Revista de investigacion clinica</title><addtitle>Rev Invest Clin</addtitle><description>The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México.
This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified.
There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006).
Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.</description><subject>Medicine, General & Internal</subject><issn>0034-8376</issn><issn>2564-8896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9UU1PAyEQ5aCxWj16NRy9bAV22Q9vpvErsTGpeiYUBsWwS4WtWn-9bGudy0smb97MvIfQKSUTVtQVv5jfTyeMpMpruocOExZZnVflCB3F-E4IY4xXB2iU56TipGCHKM5k1zvACpzDbt0u33wrcSvX-E1-ApZYW2MgQNdj5WxnlXRY-VWIgG2HZ_CdOgPG3v74eInnIF325YPTWMteYhN8m1Si7V43W7oewjHaN9JFOPnDMXq5uX6e3mUPj7f306uHTKUr-4zroiSlZLTmXGujgJS0NkxBxSVwyQtKQS8MoVX6napFk6uyqWtujNGM8Cofo8lWNyoLzov3dHeXFoqnwRgxGMMIo8muwbOmSAPn24Fl8B-r9JNobRyckR34VRSs4KxoGsZZomZbqgo-xgBGLINtZVgLSsQmDJHCELswEv_sT3q1aEH_s3dJ5L9llYQ5</recordid><startdate>20201019</startdate><enddate>20201019</enddate><creator>Córdova-Ramírez, Alejandra C</creator><creator>Sánchez-Valledor, Luisa F</creator><creator>Colón-Otero, Gerardo</creator><creator>Rivera-Alvarez, Montserrat</creator><creator>Elías-de-la-Cruz, Gilberto D</creator><creator>Murrieta-Alvarez, Iván</creator><creator>Cantero-Fortiz, Yahveth</creator><creator>León-Peña, Andrés</creator><creator>Olivares-Gazca, Juan C</creator><creator>Ruiz-Delgado, Guillermo J</creator><creator>Ruiz-Argüelles, Guillermo J</creator><general>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope></search><sort><creationdate>20201019</creationdate><title>Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center</title><author>Córdova-Ramírez, Alejandra C ; Sánchez-Valledor, Luisa F ; Colón-Otero, Gerardo ; Rivera-Alvarez, Montserrat ; Elías-de-la-Cruz, Gilberto D ; Murrieta-Alvarez, Iván ; Cantero-Fortiz, Yahveth ; León-Peña, Andrés ; Olivares-Gazca, Juan C ; Ruiz-Delgado, Guillermo J ; Ruiz-Argüelles, Guillermo J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c257t-5d4606a21855ddfce0618f2ce75ae5a5411edbf0174871cb93c69885fffd20573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Medicine, General & Internal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Córdova-Ramírez, Alejandra C</creatorcontrib><creatorcontrib>Sánchez-Valledor, Luisa F</creatorcontrib><creatorcontrib>Colón-Otero, Gerardo</creatorcontrib><creatorcontrib>Rivera-Alvarez, Montserrat</creatorcontrib><creatorcontrib>Elías-de-la-Cruz, Gilberto D</creatorcontrib><creatorcontrib>Murrieta-Alvarez, Iván</creatorcontrib><creatorcontrib>Cantero-Fortiz, Yahveth</creatorcontrib><creatorcontrib>León-Peña, Andrés</creatorcontrib><creatorcontrib>Olivares-Gazca, Juan C</creatorcontrib><creatorcontrib>Ruiz-Delgado, Guillermo J</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><jtitle>Revista de investigacion clinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Córdova-Ramírez, Alejandra C</au><au>Sánchez-Valledor, Luisa F</au><au>Colón-Otero, Gerardo</au><au>Rivera-Alvarez, Montserrat</au><au>Elías-de-la-Cruz, Gilberto D</au><au>Murrieta-Alvarez, Iván</au><au>Cantero-Fortiz, Yahveth</au><au>León-Peña, Andrés</au><au>Olivares-Gazca, Juan C</au><au>Ruiz-Delgado, Guillermo J</au><au>Ruiz-Argüelles, Guillermo J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center</atitle><jtitle>Revista de investigacion clinica</jtitle><addtitle>Rev Invest Clin</addtitle><date>2020-10-19</date><risdate>2020</risdate><volume>73</volume><issue>5</issue><spage>94</spage><epage>99</epage><pages>94-99</pages><issn>0034-8376</issn><issn>2564-8896</issn><abstract>The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México.
This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified.
There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006).
Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.</abstract><cop>Mexico</cop><pub>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</pub><pmid>33075042</pmid><doi>10.24875/RIC.20000381</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0034-8376 |
| ispartof | Revista de investigacion clinica, 2020-10, Vol.73 (5), p.94-99 |
| issn | 0034-8376 2564-8896 |
| language | eng |
| recordid | cdi_scielo_journals_S0034_83762021000200094 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Medicine, General & Internal |
| title | Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mantle%20cell%20lymphoma%20may%20have%20a%20different%20clinical%20course%20in%20Mexican%20Mestizos:%20Real-world%20data%20from%20a%20single%20center&rft.jtitle=Revista%20de%20investigacion%20clinica&rft.au=C%C3%B3rdova-Ram%C3%ADrez,%20Alejandra%20C&rft.date=2020-10-19&rft.volume=73&rft.issue=5&rft.spage=94&rft.epage=99&rft.pages=94-99&rft.issn=0034-8376&rft_id=info:doi/10.24875/RIC.20000381&rft_dat=%3Cproquest_sciel%3E2452499252%3C/proquest_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452499252&rft_id=info:pmid/33075042&rft_scielo_id=S0034_83762021000200094&rfr_iscdi=true |